Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2012, Article ID 935738, 9 pages
http://dx.doi.org/10.1155/2012/935738
Research Article

Astragaloside IV Inhibits Oxidative Stress-Induced Mitochondrial Permeability Transition Pore Opening by Inactivating GSK-3 via Nitric Oxide in H9c2 Cardiac Cells

1Department of Internal Medicine, Hebei United University, Tangshan 063000, China
2Department of Physiology, Yanbian University, Yanji 133002, China
3Heart Institute, Hebei United University, Tangshan 063000, China
4Department of Anesthesiology, The University of North Carolina at Chapel Hill, CB No. 7010, Chapel Hill, NC 27599, USA

Received 19 June 2012; Accepted 13 August 2012

Academic Editor: Paola Venditti

Copyright © 2012 Yonggui He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Yang, J. T. Lu, A. W. Zhou, B. Wang, G. W. He, and M. Z. Chen, “Antinociceptive effect of astragalosides and its mechanism of action,” Acta Pharmacologica Sinica, vol. 22, no. 9, pp. 809–812, 2001. View at Google Scholar · View at Scopus
  2. Y. Luo, Z. Qin, Z. Hong et al., “Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia,” Neuroscience Letters, vol. 363, no. 3, pp. 218–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Li, H. Y. Tao, and J. B. Chen, “Anti-apoptosis effect of astragaloside on adriamycin induced rat's cardiotoxicity,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 26, no. 11, pp. 1011–1014, 2006. View at Google Scholar · View at Scopus
  4. Z. C. Zhang, S. J. Li, Y. Z. Yang, R. Z. Chen, J. B. Ge, and H. Z. Chen, “Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis,” Journal of Asian Natural Products Research, vol. 9, no. 2, pp. 145–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Zhang, H. Zhu, C. Huang et al., “Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-γ,” Journal of Cardiovascular Pharmacology, vol. 47, no. 2, pp. 190–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Qi, L. Wei, Y. Han, Q. Zhang, A. S. Y. Lau, and J. Rong, “Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2,” International Journal of Oncology, vol. 36, no. 3, pp. 725–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. W. D. Zhang, H. Chen, C. Zhang, R. H. Liu, H. L. Li, and H. Z. Chen, “Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro,” Planta Medica, vol. 72, no. 1, pp. 4–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. X. L. Xu, X. J. Chen, H. Ji et al., “Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca 2+-ATPase,” Pharmacology, vol. 81, no. 4, pp. 325–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Y. Zhou, Y. Fan, J. L. Kong, D. Z. Wu, and Z. B. Hu, “Effects of components isolated from Astragalus membranaceus Bunge on cardiac function injured by myocardial ischemia reperfusion in rats,” Zhongguo Zhong Yao Za Zhi, vol. 25, no. 5, pp. 300–302, 2000. View at Google Scholar · View at Scopus
  10. J. Y. Hu, J. Han, Z. G. Chu et al., “Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 4, pp. 351–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. N. Weiss, P. Korge, H. M. Honda, and P. Ping, “Role of the mitochondrial permeability transition in myocardial disease,” Circulation Research, vol. 93, no. 4, pp. 292–301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. S. Suleiman, A. P. Halestrap, and E. J. Griffiths, “Mitochondria: a target for myocardial protection,” Pharmacology and Therapeutics, vol. 89, no. 1, pp. 29–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Argaud, O. Gateau-Roesch, D. Muntean et al., “Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 2, pp. 367–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Argaud, O. Gateau-Roesch, O. Raisky, J. Loufouat, D. Robert, and M. Ovize, “Postconditioning inhibits mitochondrial permeability transition,” Circulation, vol. 111, no. 2, pp. 194–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. P. Halestrap, S. J. Clarke, and S. A. Javadov, “Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection,” Cardiovascular Research, vol. 61, no. 3, pp. 372–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. J. Hausenloy, H. L. Maddock, G. F. Baxter, and D. M. Yellon, “Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?” Cardiovascular Research, vol. 55, no. 3, pp. 534–543, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. J. Hausenloy, M. R. Duchen, and D. M. Yellon, “Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury,” Cardiovascular Research, vol. 60, no. 3, pp. 617–625, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. A. Javador, S. Clarke, M. Das, E. J. Griffiths, K. H. H. Lim, and A. P. Halestrap, “Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart,” Journal of Physiology, vol. 549, no. 2, pp. 513–524, 2003. View at Google Scholar · View at Scopus
  19. G. Wang, D. A. Liem, T. M. Vondriska et al., “Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition,” American Journal of Physiology, vol. 288, no. 3, pp. H1290–H1295, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Cohen and S. Frame, “The renaissance of GSK3,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 769–776, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Frame and P. Cohen, “GSK3 takes centre stage more than 20 years after its discovery,” Biochemical Journal, vol. 359, no. 1, pp. 1–16, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Tong, K. Imahashi, C. Steenbergen, and E. Murphy, “Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective,” Circulation Research, vol. 90, no. 4, pp. 377–379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. E. R. Gross, A. K. Hsu, and G. J. Gross, “Opioid-induced cardioprotection occurs via glycogen synthase kinase b inhibition during reperfusion in intact rat hearts,” Circulation Research, vol. 94, no. 7, pp. 960–966, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Juhaszova, D. B. Zorov, S. H. Kim et al., “Glycogen synthase kinase-3β mediates convergence of protection signalling to inhibit the mitochondrial permeability transition pore,” The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1535–1549, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Gomez, M. Paillard, H. Thibault, G. Derumeaux, and M. Ovize, “Inhibition of GSK3β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion,” Circulation, vol. 117, no. 21, pp. 2761–2768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Zhou, L. Zhang, J. Xi, W. Tian, and Z. Xu, “Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells,” Alcohol and Alcoholism, vol. 44, no. 1, pp. 20–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Xi, H. Wang, R. A. Mueller, E. A. Norfleet, and Z. Xu, “Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3β and mitochondrial permeability transition pore,” European Journal of Pharmacology, vol. 604, no. 1–3, pp. 111–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Xi, W. Tian, L. Zhang, Y. Jin, and Z. Xu, “Morphine prevents the mitochondrial permeability transition pore opening through NO/cGMP/PKG/Zn2+/GSK-3β signal pathway in cardiomyocytes,” American Journal of Physiology, vol. 298, no. 2, pp. H601–H607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Xu, S. S. Park, R. A. Mueller, R. C. Bagnell, C. Patterson, and P. G. Boysen, “Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 803–812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. R. C. Scaduto and L. W. Grotyohann, “Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives,” Biophysical Journal, vol. 76, no. 1, pp. 469–477, 1999. View at Google Scholar · View at Scopus
  32. M. Akao, B. O'Rourke, Y. Teshima, J. Seharaseyon, and E. Marbán, “Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes,” Circulation Research, vol. 92, no. 2, pp. 186–194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. P. Jones, Y. Teshima, M. Akao, and E. Marbán, “Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes,” Circulation Research, vol. 93, no. 8, pp. 697–699, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Förster, I. Paul, N. Solenkova et al., “NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase,” Basic Research in Cardiology, vol. 101, no. 4, pp. 319–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Zhang, C. Zhang, R. Liu et al., “Quantitative determination of Astragaloside IV, a natural product with cardioprotective activity, in plasma, urine and other biological samples by HPLC coupled with tandem mass spectrometry,” Journal of Chromatography B, vol. 822, no. 1-2, pp. 170–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. D. J. Hausenloy, D. M. Yellon, S. Mani-Babu, and M. R. Duchen, “Preconditioning protects by inhibiting the mitochondrial permeability transition,” American Journal of Physiology, vol. 287, no. 2, pp. H841–H849, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. L. B. Becker, “New concepts in reactive oxygen species and cardiovascular reperfusion physiology,” Cardiovascular Research, vol. 61, no. 3, pp. 461–470, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Hausenloy, S. B. Ong, and D. M. Yellon, “The mitochondrial permeability transition pore as a target for preconditioning and postconditioning,” Basic Research in Cardiology, vol. 104, no. 2, pp. 189–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Di Lisa and P. Bernardi, “Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole,” Cardiovascular Research, vol. 70, no. 2, pp. 191–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. S. Park, H. Zhao, R. A. Mueller, and Z. Xu, “Bradykinin prevents reperfusion injury bytargeting mitochondrial permeability transition pore through glycogen synthase kinase 3β,” Journal of Molecular and Cellular Cardiology, vol. 40, no. 5, pp. 708–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Nishihara, T. Miura, T. Miki et al., “Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection,” Journal of Molecular and Cellular Cardiology, vol. 43, no. 5, pp. 564–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. T. Costa, S. V. Pierre, M. V. Cohen, J. M. Downey, and K. D. Garlid, “cGMP signalling in pre- and post-conditioning: the role of mitochondria,” Cardiovascular Research, vol. 77, no. 2, pp. 344–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Das, L. Xi, and R. C. Kukreja, “Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3β,” The Journal of Biological Chemistry, vol. 283, no. 43, pp. 29572–29585, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. M. Davidson, D. Hausenloy, M. R. Duchen, and D. M. Yellon, “Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection,” International Journal of Biochemistry and Cell Biology, vol. 38, no. 3, pp. 414–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. J. Hausenloy and D. M. Yellon, “New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway,” Cardiovascular Research, vol. 61, no. 3, pp. 448–460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Fulton, J. P. Gratton, T. J. McCabe et al., “Regulation of endothelium-derived nitric oxide production by the protein kinase Akt,” Nature, vol. 399, no. 6736, pp. 597–601, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Zhang, Q. Liu, L. Lu, X. Zhao, X. Gao, and Y. Wang, “Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/akt pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 2, pp. 485–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. D. J. Hausenloy, A. Tsang, M. M. Mocanu, and D. M. Yellon, “Ischemic preconditioning protects by activating prosurvival kinases at reperfusion,” American Journal of Physiology, vol. 288, no. 2, pp. H971–H976, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Hausenloy and D. M. Yellon, “Preconditioning and postconditioning: united at reperfusion,” Pharmacology and Therapeutics, vol. 116, no. 2, pp. 173–191, 2007. View at Publisher · View at Google Scholar · View at Scopus